Search for: "GLAXOSMITHKLINE LLC" Results 121 - 140 of 182
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
29 Jul 2022, 6:11 pm by Kalvis Golde
GlaxoSmithKline, LLC 22-37Issue: Whether a generic drug manufacturer’s FDA-approved label that carves out all of the language the brand manufacturer has identified as covering its patented uses can be held liable on a theory that its label still intentionally encourages infringement of those carved-out uses. [read post]
29 Jul 2024, 4:52 am by Kelly Shivery
We Help Whistleblowers Expose Fraud The Whistleblower Law Collaborative LLC helps whistleblowers expose government fraud. [read post]
ERSP Curtails Certain Purple Innovation, LLC’s Claims Promoting Its Purple Mattresses The Electronic Retailing Self-Regulation Program (“ERSP”) found that Purple Innovation, LLC, could support certain innovation claims for its Purple Mattresses, but recommended the marketer modify or discontinue other claims. [read post]
18 Sep 2016, 6:03 pm by Dennis Crouch
(cross-petition asks for recourse on failure to dance) Antitrust Reverse Payments: GlaxoSmithKline, et al. v. [read post]
8 Feb 2017, 3:09 am by Dennis Crouch
Apple Inc., No. 16-651 Antitrust Reverse Payments: GlaxoSmithKline, et al. v. [read post]
16 Jan 2017, 5:44 pm by Dennis Crouch
Apple Inc., No. 16-651 Antitrust Reverse Payments: GlaxoSmithKline, et al. v. [read post]
22 Dec 2022, 7:59 am by Dennis Crouch
GlaxoSmithKline LLC, No. 22-37, has a good chance of being heard by the Court, although it may be better for Congress to work to resolve the pending questions. [read post]
11 Jul 2012, 3:04 am by SHG
© 2012 Simple Justice NY LLC. [read post]
30 May 2019, 6:02 am by Law Offices of Jeffrey S. Glassman
GlaxoSmith Kline LLC that federal law prevented GlaxoSmithKline from adding a suicide warning label to the drug. [read post]
14 Nov 2016, 9:16 am by Dennis Crouch
(cross-petition asks for recourse on failure to dance) Antitrust Reverse Payments: GlaxoSmithKline, et al. v. [read post]
14 Jan 2013, 7:30 am by Donna Boehme
By Guest Columnist: Donna Boehme Principal at Compliance Strategists LLC and editor of the weekly CS Newsflash (and former chief compliance and ethics officer at two leading multinationals). [read post]
10 Apr 2022, 12:58 pm by Holman
Meso Scale Diagnostics, LLC, 2022 WL 1052320, — 4th —  (Fed. [read post]
3 Mar 2013, 12:06 pm by Rajiv Kr. Choudhry
Granted Soumen Ghosh 5179/KOLNP/2008 GLAXOSMITHKLINE BIOLOGICALS S.A. [read post]
24 Dec 2019, 8:06 am by Joe Mullin
Others are large incumbent companies with massive patent portfolios, like GlaxoSmithKline, Qualcomm, and IBM. [read post]
13 Oct 2016, 6:50 am by Dennis Crouch
(cross-petition asks for recourse on failure to dance) Antitrust Reverse Payments: GlaxoSmithKline, et al. v. [read post]
28 Sep 2016, 8:39 am by Dennis Crouch
(cross-petition asks for recourse on failure to dance) Antitrust Reverse Payments: GlaxoSmithKline, et al. v. [read post]
9 May 2013, 3:31 am by Cynthia Marcotte Stamer
Supreme Court’s denial of certiorari on an appeal of the Third Circuit’s decision in In Re Avandia Marketing Sales Practices GlaxoSmithKline LLC v. [read post]
11 Jun 2019, 5:12 am by Amber Walsh
GlaxoSmithKline recently announced a $300 million deal with 23 and Me to further commercialize the latter’s genetic data to identify patients with certain rare disorders for drug development and clinical trial design. [read post]